A new drug testing approach improves the detection of illicit benzodiazepine use, according to a study published in the Pain Management issue of The Journal of Applied Laboratory Medicine. Benzodiazepine abuse is second only to opioid abuse as a cause of prescription drug overdose deaths in the USA. False negatives in urine testing for benzodiazepines can give the impression that a person is not abusing the drugs or conversely that they are not taking their prescription medication and perhaps giving or selling it to a third party instead. A new method developed by Lindsay Bazydlo of the University of Virginia School of Medicine in Charlottesville, re-evaluates the standard optimized absorbance cutoff for testing based on data from liquid chromatography-tandem mass spectrometry (LC-MS/MS) and immunoassay results.
Benzodiazepine testing game changer